In the News

November 21, 2016 - Sanofi Pasteur has undertaken significant steps to restore production of ImmuCyst®/TheraCys® and to explore solutions to maintain...
- Canada's National Advisory Committee on Immunization (NACI) recognizes superior efficacy of high-dose flu vaccine for adults +65 years compared to...
August 13th, 2016  - First dengue immunization public program in the Americas starts today targeting broad age range of individuals at highest...
Quebec Science story strikes Green Gold Award winning writer outlines the pharmaceutic potential of plants   Montreal May 27, 2016 — Canada’s...
Canada’s Top Student Scientist Recognized at Sanofi Biogenius Canada National Final Iveta Demirova, 16, student at New Westminster Secondary School...
Canada’s National Advisory Committee on Immunization recognizes superior efficacy of high dose vaccine for adults 65 years of age and older...
- First marketing authorization of Dengvaxia® is a historic milestone paving the way to significantly impact dengue burden in endemic countries...
News Release     Montreal, November 17, 2015 – On behalf of the Board of Directors of Canada’s Research-Based Pharmaceutical Companies (Rx&...
- Sixty-one per cent of Canadians surveyed say the availability of an influenza vaccine covering four strains instead of three would make them more...
Every year, Sanofi Pasteur works in collaboration with the Canadian Nurses Foundation (CNF) to award a $5,000 scholarship to a nursing student who is...

Pages